



Mediphage Signs License Option Agreement with Multinational Pharmaceutical Company

Toronto, ON, January 04, 2023- Mediphage Bioceuticals (Mediphage), a preclinical-stage company developing safe and redosable non-viral gene therapies based on its proprietary ministring DNATM (msDNATM) technology announced today that it signed an Evaluation and Option agreement with an undisclosed multinational pharmaceutical company, a leader in the gene therapy space.

Mediphage has been working closely with the partner organization, conducting feasibility studies over the past 18 months, and evaluating msDNATM technology for its safety and durability of expression. As Mediphage's first Option agreement, this represents validation of Mediphage's core technology as a viable approach for non-viral gene therapies. Under the agreement, Mediphage will be responsible for the design and manufacturing of the customized msDNATM constructs, and the company will conduct the preclinical evaluation.

"We are excited to continue working with our partner on this study, developing safe and durable non-viral gene therapies. It has been a very productive relationship. The professionalism and caliber of their scientists and team is exactly what is needed to move a novel technology to the next level." said Alvaro Amorrortu, Mediphage's President and CEO.

The pharmaceutical industry is growing its interest in safe non-viral gene therapy solutions to overcome some of the limitations posed by viral-based platforms. Mediphage's msDNATM is currently being evaluated by various large pharma and biotechnology companies in applications, including gene addition, *in vivo* and *ex vivo* gene editing, and as starting material for recombinant AAV (rAAV) production.

About Mediphage

Mediphage, a Toronto-based preclinical-stage biotechnology company, is developing a next-generation non-viral gene therapy platform based on its proprietary linear, covalently closed, and double stranded ministring DNATM (msDNATM) technology. msDNATM is designed to overcome critical challenges facing viral gene therapies and leverage advancements in the non-viral delivery of nucleic acids. msDNATM is a versatile and scalable platform with applications including gene addition, *in vivo* and *ex vivo* gene editing, recombinant viral vector production, and DNA vaccines.